Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142


Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.

Antoniou AJ, Marcus C, Tahari AK, Wahl RL, Subramaniam RM.

J Nucl Med. 2014 Jul;55(7):1062-8. doi: 10.2967/jnumed.113.136770. Epub 2014 Apr 28.


Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.

Paidpally V, Tahari AK, Lam S, Alluri K, Marur S, Koch W, Wahl RL, Subramaniam RM.

J Nucl Med. 2013 Dec;54(12):2039-45. doi: 10.2967/jnumed.113.121285. Epub 2013 Oct 7.


Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival.

Marcus C, Antoniou A, Rahmim A, Ladenson P, Subramaniam RM.

J Med Imaging Radiat Oncol. 2015 Jun;59(3):281-8. doi: 10.1111/1754-9485.12286. Epub 2015 Feb 11.


¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.

Marcus C, Marashdeh W, Ahn SJ, Taghipour M, Subramaniam RM.

J Nucl Med. 2015 Jul;56(7):989-94. doi: 10.2967/jnumed.115.156240. Epub 2015 May 7.


18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.

Sheikhbahaei S, Mena E, Marcus C, Wray R, Taghipour M, Subramaniam RM.

J Nucl Med. 2016 Jun;57(6):855-60. doi: 10.2967/jnumed.115.165480. Epub 2016 Feb 2.


18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.

Marcus C, Paidpally V, Antoniou A, Zaheer A, Wahl RL, Subramaniam RM.

J Nucl Med. 2015 Feb;56(2):204-8. doi: 10.2967/jnumed.114.147884. Epub 2015 Jan 22.


18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.

Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H.

J Nucl Med. 2010 Dec;51(12):1833-40. doi: 10.2967/jnumed.110.076778. Epub 2010 Nov 15. Erratum in: J Nucl Med. 2011 Jan;52(1):106.


Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.


18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.

Mena E, Taghipour M, Sheikhbahaei S, Mirpour S, Xiao J, Subramaniam RM.

Clin Nucl Med. 2016 Sep;41(9):e403-9. doi: 10.1097/RLU.0000000000001275.


Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.

Khong PL, Huang B, Lee EY, Chan WK, Kwong YL.

J Nucl Med. 2014 Jun;55(6):911-6. doi: 10.2967/jnumed.113.131946. Epub 2014 May 12.


Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.

Marcus C, Ciarallo A, Tahari AK, Mena E, Koch W, Wahl RL, Kiess AP, Kang H, Subramaniam RM.

J Nucl Med. 2014 Sep;55(9):1411-6. doi: 10.2967/jnumed.113.136796. Epub 2014 Jun 19.


High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.

Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin E.

J Nucl Med. 2014 Nov;55(11):1786-90. doi: 10.2967/jnumed.114.144386. Epub 2014 Oct 6.


Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.

Artiko V, Odalovic S, Sobic-Saranovic D, Petrovic M, Stojiljkovic M, Petrovic N, Kozarevic N, Grozdic-Milojevic I, Obradovic V.

Hell J Nucl Med. 2015 Jan-Apr;18(1):35-41.


Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI.

J Nucl Med. 2013 Aug;54(8):1195-201. doi: 10.2967/jnumed.112.114116. Epub 2013 Jun 19.


[(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.

Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M.

Radiat Oncol. 2016 Mar 16;11:43. doi: 10.1186/s13014-016-0614-x.


FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy.

Taghipour M, Sheikhbahaei S, Wray R, Agrawal N, Richmon J, Kang H, Subramaniam RM.

AJR Am J Roentgenol. 2016 May;206(5):1093-100. doi: 10.2214/AJR.15.15604. Epub 2016 Mar 21.


Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.

Zhang C, Liao C, Penney BC, Appelbaum DE, Simon CA, Pu Y.

Radiology. 2015 Jun;275(3):862-9. doi: 10.1148/radiol.14141398. Epub 2015 Jan 14.


Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy.

Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R.

Am J Clin Oncol. 2014 Feb;37(1):77-80. doi: 10.1097/COC.0b013e31826b9cb8.


Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?

Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S, Landau D.

J Nucl Med. 2013 Jan;54(1):19-26. doi: 10.2967/jnumed.112.107375. Epub 2012 Nov 30.


Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.

Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H, Li B.

J Nucl Med. 2014 Oct;55(10):1584-90. doi: 10.2967/jnumed.114.142919. Epub 2014 Sep 11.

Supplemental Content

Support Center